Blog
RSS FeedPosted by Michael Wonder on 11 Oct 2016
NICE publishes draft guidance on the use of Otezla on the NHS
11 October 2016 - NICE has published draft guidance on the use of Otelza (apremilast) on the NHS by patients ...
Posted by Michael Wonder on 11 Oct 2016
A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK
11 October 2016 - Drug listing recommendations from health technology assessment agencies often fail to coincide with one another. ...
Posted by Michael Wonder on 04 Oct 2016
NICE published draft guidance on a new use for Keytruda
4 October 2016 - NICE has published draft guidance on the use of Keytruda (pembrolizumab) by patients with non-small-cell lung ...
Posted by Michael Wonder on 04 Oct 2016
NICE recommends new drug osimertinib for hundreds of people with lung cancer
4 October 2016 - Hundreds of people with lung cancer will now have access to new drug osimertinib, also known as ...
Posted by Michael Wonder on 04 Oct 2016
Did it matter that the Cancer Drugs Fund was not NICE? A retrospective review
3 October 2016 - This article reviews the means by which the Cancer Drugs Fund made recent funding decisions for cancer ...
Posted by Michael Wonder on 03 Oct 2016
NICE says no to daclizumab (Zinbryta)
3 October 2016 - The MS Trust is disappointed that NICE does not intend to recommend that daclizumab (Zinbryta) be made ...
Posted by Michael Wonder on 03 Oct 2016
NHS watchdog ready to impose hefty fees for approving drugs
1 October 2016 - NICE’s cost hike could deter start-ups and delay lifesaving treatments. ...
Posted by Michael Wonder on 29 Sep 2016
Cancer Drugs Fund requires further reform
27 September 2016 - Reliance on “real world” observational data undermines evidence base for clinical practice. ...
Posted by Michael Wonder on 29 Sep 2016
More on NICE recommendation of Imlygic
28 September 2016 - More on NICE's guidance on the use of talimogene laherparepvec for unresectable metastatic melanoma. ...
Posted by Michael Wonder on 29 Sep 2016
NICE rejects LIlly's Portrazza
28 September 2016 - NICE is not in favour of the use of Portrazza on the NHS. ...
Posted by Michael Wonder on 28 Sep 2016
NICE recommends the reimbursement of Imlygic
28 September 2016 - NICE has recommended the relimbursement of Amgen's new cellular therapy for patients with malignant melanoma. ...
Posted by Michael Wonder on 28 Sep 2016
Patients with BRVO, a sight threatening eye condition, now have first-line access to EYLEA (aflibercept solution for injection) on the NHS
28 September 2016 - Bayer is pleased to announce that NICE has made the final recommendation for aflibercept for the treatment ...
Posted by Michael Wonder on 27 Sep 2016
NICE sets out proposed technology assessment fees
18 September 2016 - NICE in the UK has been exploring the idea of charging the pharmaceutical industry for technology ...
Posted by Michael Wonder on 23 Sep 2016
NICE says yes to another hepatitis C drug
23 September 2016 - A new drug which effectively treats more genotypes of hepatitis C has been recommended for use in ...
Posted by Michael Wonder on 23 Sep 2016
UK audit shows infliximab biosimilars are safe, effective, and cheap
22 September 2016 - Infliximab “biosimilars”—biological therapies engineered to work in the same way as the monoclonal antibody drug infliximab (Remicade)—are ...